Compare New York Times Co (NYT) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Tempus AI — how do they compare? New York Times Co trades at $66.28 (market cap $10.47B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Tempus AI is the larger of the two by market cap, and New York Times Co pays a 1.42% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Tempus AI for 22 Days on average.
| NYT | TEM | |
|---|---|---|
Market Cap | $10.47B | $12.77B |
Volume | 1,998,850 | 8,980,490 |
Sector | Media | Broad Market / Factor |
52-Week High | $85.86 | $99.28 |
52-Week Low | $54.66 | $41.55 |
Typical Hold Time | 81 Days | 22 Days |
Enterprise Value | $9.86B | $13.40B |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.60, up 3.95% over the past 24 hours, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q1 and Q2 2026 EPS exceeding forecasts. Revenue and net income have shown steady growth from 2022 to 2025, with margins improving. The company declared a quarterly dividend of $0.23 per share, payable in October 2026. Analyst consensus is a 'Hold' with a price target of $84.00, suggesting potential upside from the current price.
Outlook remains mixed; strong fundamentals and earnings beats support growth, but a shareholder lawsuit and bearish technical indicators present near-term risks. The stock offers a dividend yield, and institutional interest is present, but investors should weigh legal uncertainties and market sentiment against solid financial performance.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
